Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCWB HCW Biologics	$3.45 +4.2%	$4.37	$2.77 ▼ $100.80	$4.97M	0.66	363,658 shs	16,833 shs
KTTA Pasithea Therapeutics	$0.72 +0.7%	$0.72	$0.65 ▼ $7.50	$5.34M	0.26	2.88 million shs	33,150 shs
THAR Tharimmune	$4.72 -5.0%	$1.62	$0.95 ▼ $6.39	$21.88M	1.17	3.17 million shs	12.69 million shs
TNFA TNF Pharmaceuticals	$0.06 -16.8%	$0.12	$0.06 ▼ $2.02	$886K	1.82	16.34 million shs	53.39 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCWB HCW Biologics	-2.65%	-23.73%	-23.38%	-60.45%	-80.72%
KTTA Pasithea Therapeutics	+0.98%	+1.34%	-1.10%	-22.20%	-85.10%
THAR Tharimmune	+38.44%	+276.52%	+206.79%	+266.09%	+74.39%
TNFA TNF Pharmaceuticals	-20.86%	-26.59%	-29.81%	-56.94%	+7,509,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCWB HCW Biologics	2.1845 of 5 stars	3.5	3.0	0.0	0.0	1.5	1.7	0.0
KTTA Pasithea Therapeutics	1.2416 of 5 stars	0.0	5.0	0.0	0.0	2.9	0.0	0.6
THAR Tharimmune	3.3622 of 5 stars	3.8	5.0	0.0	0.0	2.2	2.5	0.0
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCWB HCW Biologics	3.00	Buy	$35.00	914.49% Upside
KTTA Pasithea Therapeutics	0.00	N/A	N/A	N/A
THAR Tharimmune	3.50	Strong Buy	$17.00	260.17% Upside
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TNFA, HCWB, KTTA, and THAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCWB HCW Biologics	$2.57M	1.93	N/A	N/A	($0.04) per share	-86.25
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
THAR Tharimmune	N/A	N/A	N/A	N/A	$0.08 per share	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCWB HCW Biologics	-$30.02M	-$14.04	N/A	∞	N/A	-1,368.55%	N/A	-40.72%	N/A
KTTA Pasithea Therapeutics	-$13.90M	-$7.55	N/A	∞	N/A	N/A	-88.60%	-81.10%	N/A
THAR Tharimmune	-$12.20M	-$6.10	N/A	∞	N/A	N/A	-1,239.20%	-365.06%	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$2.31	N/A	∞	N/A	N/A	-69.21%	-33.98%	N/A

Latest TNFA, HCWB, KTTA, and THAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	TNFA TNF Pharmaceuticals	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/18/2025	Q2 2025	HCWB HCW Biologics	$1.80	-$6.79	-$8.59	-$6.79	$7.00 million	$0.01 million
8/14/2025	Q2 2025	KTTA Pasithea Therapeutics	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/14/2025	Q2 2025	THAR Tharimmune	-$0.58	-$0.64	-$0.06	-$0.64	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
THAR Tharimmune	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCWB HCW Biologics	N/A	0.11	0.07
KTTA Pasithea Therapeutics	N/A	4.97	3.84
THAR Tharimmune	N/A	1.17	0.67
TNFA TNF Pharmaceuticals	N/A	0.93	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCWB HCW Biologics	2.96%
KTTA Pasithea Therapeutics	23.92%
THAR Tharimmune	1.16%
TNFA TNF Pharmaceuticals	9.64%

Insider Ownership

Company	Insider Ownership
HCWB HCW Biologics	42.70%
KTTA Pasithea Therapeutics	2.70%
THAR Tharimmune	10.01%
TNFA TNF Pharmaceuticals	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCWB HCW Biologics	40	1.44 million	825,000	Not Optionable
KTTA Pasithea Therapeutics	3	7.44 million	7.24 million	Not Optionable
THAR Tharimmune	2	4.64 million	4.17 million	Not Optionable
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A

TNFA, HCWB, KTTA, and THAR Headlines

Recent News About These Companies

TNF Pharmaceuticals announces improved financial position

August 20 at 3:02 AM | msn.com

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

August 19 at 5:20 PM | businesswire.com

TNF Pharmaceuticals Inc Ordinary Shares TNFA - Morningstar

July 11, 2025 | morningstar.comM

TNF Pharmaceuticals, Inc. (TNFA) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

June 25, 2025 | finance.yahoo.com

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules

May 9, 2025 | tipranks.com

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025 | businesswire.com

TNF Pharmaceuticals uses AI to refine patient selection for trials

April 24, 2025 | uk.investing.com

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

April 22, 2025 | finance.yahoo.com

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

April 22, 2025 | msn.com

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

April 17, 2025 | finance.yahoo.com

TNF Pharmaceuticals, Inc. Common Stock (TNFA) Short Interest

April 3, 2025 | nasdaq.com

TNF Pharmaceuticals faces Nasdaq delisting over price

March 23, 2025 | investing.com

TNF Pharmaceuticals, Inc. Common Stock

March 20, 2025 | fxempire.comF

TNF Pharmaceuticals shares R&D progress on Isomyosamine

March 12, 2025 | uk.investing.com

TNF Pharmaceuticals initiates isomyosamine trial

February 25, 2025 | markets.businessinsider.com

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

February 25, 2025 | businesswire.com

TNFA stock touches 52-week low at $0.48 amid market challenges

February 14, 2025 | msn.com

TNFA stock touches 52-week low at $1.02 amid market challenges

January 30, 2025 | msn.com

How Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?

January 30, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, HCWB, KTTA, and THAR Company Descriptions

HCW Biologics NASDAQ:HCWB

$3.45 +0.14 (+4.23%)

Closing price 03:59 PM Eastern

Extended Trading

$3.46 +0.01 (+0.43%)

As of 06:13 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Pasithea Therapeutics NASDAQ:KTTA

$0.72 +0.01 (+0.70%)

Closing price 03:54 PM Eastern

Extended Trading

$0.70 -0.02 (-3.08%)

As of 06:36 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Tharimmune NASDAQ:THAR

$4.72 -0.25 (-5.03%)

Closing price 04:00 PM Eastern

Extended Trading

$4.86 +0.14 (+2.97%)

As of 07:20 PM Eastern

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

TNF Pharmaceuticals NASDAQ:TNFA

$0.06 -0.01 (-16.78%)

Closing price 04:00 PM Eastern

Extended Trading

$0.07 +0.01 (+9.76%)

As of 07:21 PM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time